Company Profile For ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (ACAD.O) (Consolidated Issue listed on NASDAQ Global Market)

sector: Healthcare · industry: Biotechnology ·

As of 8:48pm IST

1.33USD

Price Change

+0.01

Percent Change

+0.76%

Analyst Recommendations

Overview

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Quick Financial Synopsis

BRIEF: For the six months ended 30 June 2009, ACADIA Pharmaceuticals Inc.'s revenues totaled $2.2K, up from $983K. Net loss decreased 20% to $27.7M. Revenues reflects increased collaboration revenues. Lower loss reflects improved gross & operating margin, a decrease in research & development expenses, lower general & administrative expenses, decreased stock based compensation expenses and lower interest expenses.